Additionally, Shoji et al. found in 96 advanced GC patients treated with nivolumab that baseline PD-L1+, B7H3+, and CD115+ myeloid cell subsets, as well as post-treatment LAG3+, CD155+, and CD115+ myeloid cell subsets, were associated with poorer PFS and OS [154]. Here, CSF1R is linked to gastric cancer.